RESULTS OF THE MULTI-CENTRIC STUDY RENACED DIABETES TIPO 1 IN MEXICO

R. Faradji¹, M. Valenzuela-Lara², A.P. Diaz-Barriga Menchaca³, C.A. Antillón Ferreira⁴, J.F. Bustamante Martinez⁵, M.P. Ceceña Gonzalez⁶, N.E. De la Garza Hernandez⁷, M. Guajardo Jaquez⁸, L. Islas Ortega⁹, A. Martínez Ramos Mendez¹⁰, M.A. Mendoza Romo¹¹, M.A. Polanco Preza¹², H.G. Rangel Gerrero¹³, M. Tavera Hernandez¹⁴, J.C. Valenzuela Montoya¹⁶, M. Vidrio Velazquez¹⁶, A.E. Yepez Rodriguez¹⁷, R. Niño Vargas¹⁸, M.E. Sainz de la Maza Viadero¹⁹, C. Magis-Rodriguez². **RENACED DIABETES TIPO 1 RESEARCH GROUP. MEXICO.**

BACKGROUND AND AIMS

Information regarding type 1 diabetes (T1D) patients' follow-up in Mexico is limited. An online- system, RENACED DT1, registers longitudinal T1D data in Mexico.

METHODS

Descriptive analysis of 894 T1D patients registered on RENACED DT1, in 17 Mexican States, until 10/8/2017.

RESULTS

Fifty percent of the patients were diagnosed in the last 10 years, 530 patients were women (59.3%) and 364 patients were men (40.7%). The average age of diagnosis was 12.5 years, being men 2 years younger than women (11.78 vs. 13.02) at diagnosis (p=0.0289) (Image 1).





Image 1: Patients age at diagnosis by sex

At the time of the analysis, 860 patients remain active, 40% men (M) and 60% women (W), with a ratio W:M of 1.5. Of this, 58% were being taken care in 3 states: Jalisco, Mexico City and Nuevo Leon.

The average age was 24.6 years old (yo), being women significantly (p=0.0268) older than men (25.4 vs. 23.4); nevertheless, 50% of the active patients were younger than 22 yo (Image 2).





Twelve percent have family history of T1D and 57.5% of T2D.

Mean BMI of active patients was 22.3 Kg/m² (n=679) with no significant differences between men (22.2 Kg/m²) and women (22.4 Kg/m²); and a mean HbA1c of 8.5% (n=617), without significant differences between men (8.4%) and women (8.6%).


38.1% performs SMBG (self-monitoring of blood glucose) ≥ 4 times/day, 23% are on insulin-pumps and 66% are on basal-bolus regimen by injections.

Patients that perform SMBG \geq 4 times/day, had lower HbA1c levels (8.08; Cl95% 7.9–8.3) than those that monitor less (8.7; Cl 95% 8.4–8.9) (p<0.05) (Table 1).

Table 1. Times of SMBG vs. HbA1c	
≥4 times/day	8.08 (7.9-8.3)
<4 times/day	8.7 (8.4-8.9)

A lower HbA1c level (<0.05) was observed in patients that used a continuous glucose monitor (CGM) (8.0; Cl 95% 7.5–8.5) than in those who did not (8.8; Cl 95% 8.5–9.0). A total of 20.9% and 12.1% of patients had HbA1c <7% and 7<7.5%, respectively.

The presence of mild/moderate hypoglycemia was high (74.6%), as well as that of severe hypoglycemia (26.3%), the presence of chronic complications was 12.2%. (Image 3)



CONCLUSIONS

The percentage of T1D patients in Mexico that reach the HbA1c target is low (20.9 % <7% and 33% < 7.5%), but similar to what is described in the literature. Improved glucose monitoring technology, insulin delivery systems and adjunctive therapy for T1D will hopefully help improve glycemic control in T1D patients.